Lumida
/PRVA
⌘K
Privia Health Group Inc

Privia Health Group Inc

PRVA
$26.90USD↓-1.18%-0.32 today

MARKET CAP

3.4B

P/E (TTM)

168.1x

FWD P/E

73.4x

DAY RANGE

$27 – $28

52W RANGE

$19
$29

AI Summary

Stalk
StalkMedium

PRVA is in a Stage 2 advance with a steep Parabola continuation pattern, rising EMAs, and a persistent higher-high/higher-low structure confirming medium-term bullish bias. However, price is extended above the 9/21 EMAs with RSI and Options Score in overbought territory, signaling pullback risk. Execution should be deferred, stalking for pullbacks into the rising EMA support zone for an optimal entry.

  • ↑Q1 revenue $862.9M (+12.8% YoY) and adjusted EBITDA $36.7M (+36.3%) highlight strong financial momentum.
  • ↑Attributed lives grew 26.5% YoY to 1.6M and providers increased 13.6% to 5,535.
  • ↓Weak business quality metrics signal potential operational and balance sheet vulnerabilities.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Privia Health, Inc. (NASDAQ: PRVA) operates as a leading healthcare technology company specializing in value-based care delivery. The company's innovative approach aggregates community-based medical groups and risk-bearing entities via a comprehensive tech and services platform, enhancing patient outcomes and cost-efficiency. Currently, Privia serves over 5.9 million patients across 24 states and the District of Columbia, significantly expanding its footprint amidst a favorable growth environment in the healthcare sector.

Bull says

  • ↑Q1 revenue $862.9M (+12.8% YoY) and adjusted EBITDA $36.7M (+36.3%) highlight strong financial momentum.
  • ↑Attributed lives grew 26.5% YoY to 1.6M and providers increased 13.6% to 5,535.
  • ↑Cash balance $419.5M with zero debt; aims to convert 80% of EBITDA into free cash flow.
  • ↑Acquisition of Avalent Health’s ACO business expands value-based care network and attributed lives.
  • ↑Demographic tailwinds in Medicare Advantage support ~20% EBITDA growth guidance for 2026.
  • ↑Strong growth and earnings yield factors combined with low leverage underpin valuation appeal.

Bear says

  • ↓Weak business quality metrics signal potential operational and balance sheet vulnerabilities.
  • ↓Evolving Medicare Advantage regulations may reduce reimbursements and pressure future earnings.
  • ↓Executives sold over $4M in shares, raising investor sentiment concerns.
  • ↓Integration of Avalent ACO may delay care margin improvements and disrupt performance.
  • ↓Intense competition in value-based care risks pricing pressure and erosion of market share.
  • ↓Elevated volatility and weak profitability factors amplify downside risk for investors.

Investment themes with PRVA

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026bullish

Transcript signals

Bull points

  • Privia Health delivered a strong first quarter as we continue to execute extremely well and drive growth across our markets.
  • We ended the first quarter with 5,535 providers, a 13.6% increase year-over-year, and with 1.6 million value-based attributed lives, up 26.5% from a year ago.
  • The combination of implemented provider growth, attribution growth, and value-based performance helped increase practice collections 14.6% from the first quarter last year.

Bear points

  • I think you're right. There was a lot of investments done, VCs entering the space, private equity being very aggressive. I think with all of that dissipating, I think it bodes well for a business like Privia with a very strong balance sheet and free cash flow profile.
  • I think it's going to be tough. The changes to, you know, the Medicaid or the ACA exchange population and how that filters through different health systems is going to also add pressure.
  • I think with all of that dissipating, I think it bodes well for a business like Privia with a very strong balance sheet and free cash flow profile.
Read full transcript analysis ›